The dPCR and qPCR market size is projected to reach US$ 18,230.74 million by 2030 from US$ 8,976.99 million in 2022. The market is expected to register a CAGR of 9.30% during 2022–2030. The development of droplet digital PCR will likely remain a key trend in the market.
Nucleic acid quantification in molecular biology is facilitated by two essential technologies: quantitative PCR (qPCR) and digital PCR (dPCR). The market is expected to grow due to ongoing innovations that improve PCR technologies' accuracy, efficiency, and affordability and the integration of AI and machine learning for improved data analysis and interpretation. The leading companies in the market are Agilent Technologies Inc., QIAGEN N.V., Roche Diagnostics, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories, Inc. The demand for dPCR and qPCR is expected to grow significantly due to rising disease prevalence, technological advancements, and increased research and development. Nevertheless, despite obstacles like exorbitant expenses and technological constraints, the market offers profitable prospects for advancement and growth, especially in developing nations.
In the domains of recombinant DNA technology, which encompasses recombinant protein synthesis and PCR technology for amplification and quantification goals, gene synthesis is the most widely recognized instrument. In 2021, Mercia led a US$10 million Series A funding round for Camena Bioscience, a synthetic biology startup that supplies genes to the biotechnology and pharmaceutical industries. With the extra cash, the business will grow and continue to develop its revolutionary DNA synthesis platform, gSynth. The technology platform and other relevant resources accelerate the company's development of gene synthesis. Additionally, businesses have expanded the funds allocated to research and development to improve gene synthesis. The completion of its Series B funding round was announced in 2020 by EVONETIX LTD, a synthetic biology startup developing a desktop platform for high-fidelity, quick, and scalable gene synthesis. In this round, the business raised US$ 30 million (£23 million) under the direction of new investor Foresite Capital. Along with Rising Tide Fund and Civilization Ventures, other investors who took part in the round included Draper Esprit, DCVC (Data Collective), the Morningside group, Providence Investment Company, and Cambridge Consultants Ltd. Thus, growing government company investments support the expansion of the global gene synthesis market.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
dPCR and qPCR Market: Strategic Insights
In most molecular biology labs, the polymerase chain reaction (PCR) is a robust, nearly universal technology used to amplify specific DNA stretches for genotyping, cloning, and analyzing single nucleotide variations. It is also the foundation for most next-generation sequencing (NGS) preparations. Technological advancements are producing different kinds of PCR techniques. Currently, PCR technology is being investigated for several unconventional uses, which will facilitate and expedite molecular diagnosis. Specifically, digital and real-time PCR improvements are utilized to support forensic investigations, identify viruses and bacteria, and diagnose illnesses.
Additionally, the researchers are attempting to use some nanomaterials to shorten test times. Announcing the development of ultrafast PCR technology in March 2023 was the Center for Augmented Safety System with Intelligence, Sensing of the Korea Institute of Science and Technology (KIST, President: Seok Jin Yoon). The research team led by Dr. Sang Kyung Kim and Dr. Seungwon Jung made this announcement. Using photothermal nanomaterials, the ultrafast PCR cuts the test duration in half compared to the previous test. The new method takes five minutes to complete and has diagnostic performance comparable to the current test method. Therefore, the growth of the dPCR and qPCR markets is driven by technological advancements in PCR technologies.
Molecular techniques like PCR have advanced as diagnostic tools in recent years. The technique is regarded as an essential research and diagnostic tool because it allows medical professionals to accurately diagnose a wide range of infectious diseases. With PCR, a single DNA strand can produce millions of copies of itself. It also makes early disease diagnosis possible, which makes it crucial for disease control. It is widely accepted because PCR produces consistent results that can be compared across labs. PCR methods are becoming more popular in developing nations. The World Health Organization is offering the required technical assistance to establish PCR laboratories in each of the 11 WHO South East Asia member states, according to the World Health Organization Report on Establishment of PCR Laboratory in Developing Countries (2016). The labs will support the delivery of top-notch healthcare. Depending on their needs, these PCR labs have embraced various PCR technologies, including digital PCR (dPCR), multiplex PCR, real-time PCR, in-situ PCR, and reverse transcriptase PCR (RT-PCR). As a result of its ease of use, speed, and high specificity in disease screening, as well as its growing applications in clinical microbiology, virology, parasitology, biotechnology, and related fields, the dPCR and qPCR market in developing nations is anticipated to grow significantly over the following years.
Key segments that contributed to the derivation of the dPCR and qPCR market analysis are treatment, product, application, and end user.
The geographic scope of the dPCR and qPCR market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
The US, Canada, and Mexico comprise the North American dPCR and qPCR market segments. The US and Canada have the most significant market shares in North America, the region's primary biotechnology market. The presence of key market players, a rise in demand for innovative products from bio-analytical instrument manufacturers and PCR companies, and extensive research and development across multiple academic and research institutes all contribute to the market growth in North America. The growing emphasis on using advanced techniques in healthcare, public and private efforts to advance precision medicine, and significant funding for genomic research from public and private sources are all anticipated to spur growth and significantly increase revenue generation for North America's dPCR and qPCR markets. Furthermore, the nation's research groups have made scientific advancements that align with the region's growth and dominance in the global market positioning.
The regional trends and factors influencing the dPCR and qPCR Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses dPCR and qPCR Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 8,976.99 Million |
| Market Size by 2030 | US$ 18,230.74 Million |
| Global CAGR (2022 - 2030) | 9.30% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The dPCR and qPCR Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the dPCR and qPCR Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The dPCR and qPCR market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the dPCR and qPCR market are listed below:
The “dPCR and qPCR Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
The development of droplet digital PCR will likely remain a key trend in the market.
Abbott Laboratories, Thermo Fisher Scientific Inc., Qiagen NV, Standard Biotools Inc., Takara Bio Inc., Lepu Medical Technology, F. Hoffmann-la Roche Ltd, Bio-rad Laboratories Inc, Beijing Co Ltd, Agilent Technologies Inc.
The market is expected to register a CAGR of 9.30% during 2022–2030.
North America dominated the dPCR and qPCR market in 2022
Key factors driving the market are the increasing incidence of genetic and infectious diseases, rising investments and funds for gene synthesis, and technological advancements in PCR technologies.